Biotech Values

[iwfal]

SNTA -

Based on my experience working with oncology trials, it should be less than 10%, although that percentage could be higher among patients with short PFS duration as discussed in the first reply.

How much does that vary with cancer-type and treatment-type? Because the crude numbers (e.g. small trials, ...) I *have* seen were meaningfully higher than 10% but not necessarily in this disease.